381 related articles for article (PubMed ID: 14516099)
1. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
2. A radiobiological investigation on dose and dose rate for permanent implant brachytherapy of breast using 125I or 103Pd sources.
Baltas D; Lymperopoulou G; Löffler E; Mavroidis P
Med Phys; 2010 Jun; 37(6):2572-86. PubMed ID: 20632569
[TBL] [Abstract][Full Text] [Related]
3. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
4. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
5. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
6. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
7. Edema-induced increase in tumour cell survival for 125I and 103Pd prostate permanent seed implants--a bio-mathematical model.
Yue N; Chen Z; Nath R
Phys Med Biol; 2002 Apr; 47(7):1185-204. PubMed ID: 11996063
[TBL] [Abstract][Full Text] [Related]
8. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy.
Wang JZ; Mayr NA; Nag S; Montebello J; Gupta N; Samsami N; Kanellitsas C
Med Phys; 2006 Apr; 33(4):1025-32. PubMed ID: 16696479
[TBL] [Abstract][Full Text] [Related]
9. Prescription dose in permanent (131)Cs seed prostate implants.
Yue N; Heron DE; Komanduri K; Huq MS
Med Phys; 2005 Aug; 32(8):2496-502. PubMed ID: 16193779
[TBL] [Abstract][Full Text] [Related]
10. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
11. Optimum timing for image-based dose evaluation of 125I and 103PD prostate seed implants.
Yue N; Chen Z; Peschel R; Dicker AP; Waterman FM; Nath R
Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):1063-72. PubMed ID: 10571216
[TBL] [Abstract][Full Text] [Related]
12. Isotope selection for patients undergoing prostate brachytherapy.
Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
[TBL] [Abstract][Full Text] [Related]
13. Effect of prostate size and isotope selection on dosimetric quality following permanent seed implantation.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Tech Urol; 2001 Sep; 7(3):233-40. PubMed ID: 11575521
[TBL] [Abstract][Full Text] [Related]
14. Analysis of the relationship between prescribed dose and dosimetric advantage of real-time intraoperatively built custom-linked seeds in iodine-125 prostate brachytherapy.
Hirose K; Aoki M; Sato M; Akimoto H; Hashimoto Y; Imai A; Kamimura N; Kawaguchi H; Hatayama Y; Fujioka I; Tanaka M; Ohyama C; Takai Y
Radiat Oncol; 2017 Dec; 12(1):192. PubMed ID: 29191234
[TBL] [Abstract][Full Text] [Related]
15. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
Butler WM; Merrick GS; Dorsey AT; Lief JH
Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
[TBL] [Abstract][Full Text] [Related]
16. Dosimetric assessment of prostate cancer patients through principal component analysis (PCA).
Gloi AM; Buchanan R
J Appl Clin Med Phys; 2013 Jan; 14(1):3882. PubMed ID: 23318379
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric evaluation of high-dose-rate interstitial brachytherapy boost treatments for localized prostate cancer.
Fröhlich G; Agoston P; Lövey J; Somogyi A; Fodor J; Polgár C; Major T
Strahlenther Onkol; 2010 Jul; 186(7):388-95. PubMed ID: 20582396
[TBL] [Abstract][Full Text] [Related]
18. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
19. Influence of source batch S dispersion on dosimetry for prostate cancer treatment with permanent implants.
Nuñez-Cumplido E; Perez-Calatayud J; Casares-Magaz O; Hernandez-Armas J
Med Phys; 2015 Aug; 42(8):4933-40. PubMed ID: 26233219
[TBL] [Abstract][Full Text] [Related]
20. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer.
Nag S; Beyer D; Friedland J; Grimm P; Nath R
Int J Radiat Oncol Biol Phys; 1999 Jul; 44(4):789-99. PubMed ID: 10386635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
